

## **ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN** PATIENTS WITH NASH TREATED WITH OBETICHOLIC ACID: **RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL**

Helena Cortez-Pinto<sup>1</sup>, Zobair M. Younossi<sup>2,3</sup>, Maria Stepanova<sup>4</sup>, Fatema Nader<sup>4</sup>, Rohit Loomba<sup>5</sup>, Quentin M. Anstee<sup>6</sup>, Vlad Ratziu<sup>7</sup>, Stephen Harrison<sup>8</sup>, Arun J. Sanyal<sup>9</sup>, James Trotter<sup>10</sup>, Muhammad Y. Sheikh<sup>11</sup>, Aldo J. Montano-Loza<sup>12</sup>, Antonio Olveira<sup>13</sup>, Laura Stinton<sup>14</sup>, David Sheridan<sup>15</sup>, Victor Vargas<sup>16</sup>, Lise Lotte Gluud<sup>17</sup>, Rifaat Safadi<sup>18</sup>, Jörn M. Schattenberg<sup>19</sup>, Mandana Khalili<sup>20</sup>, David Orr<sup>21</sup>, Markus Peck-Radosavljevic<sup>22</sup>, Michael Allison<sup>23</sup>, Gail Cawkwell<sup>24</sup>, Bruce Wong<sup>24</sup>, Pierre Bedossa<sup>25</sup>, Zachary Goodman<sup>2</sup>, and Mary Rinella<sup>26</sup> on behalf of the REGENERATE Study Investigators

1. Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; 2. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States; 3. Center for Liver Diseases, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, United States; 4. Center for Outcomes Research in Liver Disease, Washington, DC, United States; 5. University of California San Diego, CA, United States; 6. Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; 7. Sorbonne Université, Hôpital Pitié – Salpêtrière, Paris, France; 8. Pinnacle Clinical Research Center, San Antonio, TX, United States; 9. Virginia Commonwealth University, Richmond, VA, United States; 10. Texas Digestive Disease Consultants, Dallas, TX, United States; 11. Fresno, CA, United States; 12. Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada; 13. Hospital Universitario La Paz, Madrid, Spain; 14. University of Calgary, Calgary, Canada; 15. University Hospitals Plymouth NHS Trust and University of Plymouth, United Kingdom; 16. Hospital Vall d'Hebron, Universitat Autònoma, CIBERehD, Barcelona, Spain; 17. Copenhagen University Hospital Hvidovre, Denmark; 18. Hadassah Medical Organization, & Holy Family Medical Center, Nazareth, Israel; 19. Department of Medicine, University Medical Center, Mainz, Germany; 20. University of California San Francisco, San Francisco, CA, United States; 21. Auckland City Hospital, Auckland, New Zealand; 22. Abteilung Innere Medizin und Gastroenterologie (IMuG), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria; 23. Addenbrookes Hospital, Cambridge, United Kingdom; 24. Intercept Pharmaceuticals, Inc., New York, NY, United States; 25. Service d'Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, France; 26. Feinberg School of Medicine, Northwestern University, Chicago, IL, United States

HC-P: TBD; ZMY: Consultancy fee from BMS, Novartis, AbbVie, Merck, Novo Nordisk, Intercept, Viking, Terns, Gilead, and Shionogi; MS: TBD; FN: TBD; FN: TBD; FN: TBD; FN: TBD; FN: TBD; TBD; FN: Ingelheim, 89bio Ltd., and BMS; grant/research support from Eli Lilly, Gilead, Galmed, NGM, Merck, Prometheus, Intercept, Janssen, Novo Nordisk, Boehringer Ingelheim, Siemens, Novartis, Rovo Nordisk, Pfizer, Poxel, ProSciento, Raptor Pharma, Servier, Viking Therapeutics, Galmed, Genfit, Gilead, Grunthal, HistoIndex, Indalo, Imperial Innovations, Intercept, Inventia, IQVIA, Janssen, Kenes, Abbott Laboratories, Acuitas Medical, Allergan/Tobira, AstraZeneca, GSK, Glympse Bio, Novartis, Pfizer, and Vertex; speaking and teaching for Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, and MedScape; VR: Consultancy fee from Gilead and Intercept; SH: Consultancy fee from Gilead and Intercept; SH: Consultancy fee from RedX, IFMO, Lipocine, Innovate, Zydus, AMRA, HemoShear Lilly, Novo Nordisk, AstraZeneca, Pfizer, Terns, Sunrise, Immuron, OWL, and Bird Rock; grant/research support from Intercept, Allergan, Novartis, Merck, BMS, Boehringer Ingelheim, Echosens, and Gilead; stock shareholder at Genfit, Sanyal Biotechnologies, Gilead, Galmed, Exhalenz, Durect, Indalo, and Tiziana; advisory committee/review panel at Axcella Health; JT: TBD; MYS: TBD; AJM-L: TBD VV: TBD; LLG: TBD; RS: TBD; JMS: Consultancy fee from BMS, Boehringer Ingelheim, Genfit, Gilead, Intercept, Genfit, Gilead, Intercept, Genfit, Allergan, Poxel, Echosens, Inventiva, Madrigal, CymaBay, HistoIndex, Sanofi MSD, BMS, OWL, Diafir; ZG: Grant support from Gilead, Galectin, Conatus, Novartis, BMS, Allergan, and Alexion; MR: Consultancy fee from Genfit, Gilead, Intercept, NGM, Merck, Viking, Metacrine, BMS, Gelesis, Fractyl, Pfizer, Madrigal, Enanta, Echosens, and Novartis; grant/research support from Novartis; grant/research support from Genfit, Gilead, Cirius, NGM, Conatus, Allergan, and Enanta.

# **INTRODUÇÃO**

- Obeticholic acid (OCA) was shown to improve fibrosis without worsening of steatohepatitis in the interim analysis of the REGENERATE phase 3 clinical trial<sup>1</sup>
- Our aim was to assess patient-reported outcomes (PROs) in NASH patients and the effects of treatment with OCA

# MATERIAL/MÉTODOS

- Non-cirrhotic NASH patients were enrolled in a phase 3, double-blind, randomized, placebo-controlled, multicenter study of OCA (REGENERATE; #NCT02548351)
- The Chronic Liver Disease Questionnaire-NASH (CLDQ-NASH), Work Productivity and Activity Impairment (WPAI), EuroQol (EQ-5D), and Impact of Weight on Quality of Life-Lite (IWQL) were administered at baseline, 6, 12, and 18 months


## RESULTADOS

**Table 1.** Clinico-demographic characteristics by REGENERATE treatment arm.

	Placebo	OCA 10 mg	OCA 25 mg	р	All
Ν	407	407	404		1,218
Age, years	53.6 ± 11.7	54.4 ± 11.0	54.2 ± 11.8	0.62	54.1 ± 11.5
Age at diagnosis, years	50.5 ± 12.0	51.0 ± 11.3	50.1 ± 12.4	0.68	50.5 ± 11.9
Enrolled in the U.S.	281 (69.0%)	280 (68.8%)	270 (66.8%)	0.76	831 (68.2%)
Male gender	176 (43.2%)	177 (43.5%)	171 (42.3%)	0.94	524 (43.0%)
White	338 (91.6%)	343 (90.7%)	325 (86.9%)	0.08	1006 (89.7%)
Employed	196 (59.2%)	174 (53.9%)	156 (48.9%)	0.0308	526 (54.1%)
Current smoker	35 (8.6%)	35 (8.6%)	40 (9.9%)	0.76	110 (9.0%)
Fibrosis stage 1	96 (23.6%)	95 (23.3%)	96 (23.8%)	0.99	287 (23.6%)
Fibrosis stage 2	142 (34.9%)	130 (31.9%)	139 (34.4%)	0.63	411 (33.7%)
Fibrosis stage 3	169 (41.5%)	182 (44.7%)	169 (41.8%)	0.60	520 (42.7%)
Type 2 diabetes	220 (54.1%)	219 (53.8%)	224 (55.4%)	0.88	663 (54.4%)
Baseline TZD/Glitazones/Vit. E	56 (13.8%)	57 (14.0%)	54 (13.4%)	0.97	167 (13.7%)
BMI, kg/m²	34.3 ± 5.9	33.9 ± 5.6	33.8 ± 5.5	0.62	34.0 ± 5.6
APRI score	0.737 ± 0.535	0.722 ± 0.498	0.735 ± 0.581	0.98	0.732 ± 0.539
ELF score	9.55 ± 0.93	9.63 ± 0.92	9.60 ± 0.93	0.37	9.59 ± 0.93
FIB-4 score	1.52 ± 0.83	1.55 ± 0.84	$1.52 \pm 0.82$	0.71	1.53 ± 0.83
NAS score (0-8)	5.84 ± 1.11	5.82 ± 1.11	5.87 ± 1.08	0.83	5.85 ± 1.10
NAS: Ballooning (0-2)	$1.69 \pm 0.46$	1.67 ± 0.47	$1.68 \pm 0.47$	0.89	$1.68 \pm 0.47$
NAS: Lobular inflammation (0-3)	2.19 ± 0.77	2.21 ± 0.73	$2.22 \pm 0.74$	0.92	$2.20 \pm 0.75$
NAS: Steatosis (0-3)	1.97 ± 0.85	1.94 ± 0.86	$1.97 \pm 0.88$	0.86	1.96 ± 0.86


- There were 1,218 NASH patients; 43% had stage 3 fibrosis (Table 1)
- Patients were randomized to receive 10 mg (N=407) or 25 mg (N=404) of OCA or placebo (N=407) (Table 1)
- Baseline PRO scores were similar between three treatment groups (all p>.05)
- Baseline EQ-5D utility score 0.814 ± 0.173 was significantly lower than age- and country-matched population norm 0.855 (p<0.0001)


Figure 2. Mean changes from baseline in select PRO scores by treatment arm.



Note: The changes are shown as arithmetic means ± 95% CI.

#### Figure 3. Changes in CLDQ-NASH scores from baseline to month 18 by treatment outcome.





Note: The changes are shown as arithmetic means ± 95% CI. (A) CLDQ-NASH (range 1-7); (B) EQ-5D (transformed to 0-100); (C) WPAI (ranges 0-1, higher scores indicate worse impairment); (D) IWQL (transformed to 0-100)

## CONCLUSÕES

- The baseline quality of life for non-cirrhotic patients with NASH is below population norms, suggesting that NASH is not an asymptomatic disease
- None of PRO domains measured during REGENERATE were negatively affected by OCA, while effective treatment of NASH could improve PRO scores

### REFERÊNCIAS

1. Younossi Z, et al. International Liver Congress 2019; Vienna, Austria.

### **CORRESPONDING AUTHOR**

Helena Cortez-Pinto; hlcortezpinto@netcabo.pt

### **ACKNOWLEDGMENTS**

Medical editorial assistance was provided by Peloton Advantage, LLC, an OPEN Health company, with financial support from Intercept Pharmaceuticals, Inc.

Note: The changes are shown as arithmetic means ± 95% CI; observed cases only; \* p<0.05, \*\* p<0.01.

- During treatment, compared to baseline, consistent PRO improvement was observed: p<0.05 (by a sign rank test) for 12 out of 24 calculated domain and summary PRO scores by treatment month 18 in the pooled cohort (Figure 1)
- For 25 mg OCA, improvements in Abdominal and Worry domains of CLDQ-NASH over time were significantly greater than in the other treatment arms (p=0.013 and 0.043 by repeated measures ANOVA, respectively) (Figure 2); all other PRO score trends were similar between the two actively treated groups and placebo (p>0.05)
- In multivariate regression analysis, OCA 25 mg was independently associated with a greater improvement in CLDQ-NASH Abdominal score:  $\beta$ =0.26±0.10, p=0.006
- In patients who experienced fibrosis improvement, NAS score decrease (by ≥2 points), or NASH resolution, improvements exceeding the minimal clinically important difference threshold were noted in some CLDQ-NASH domains (MCID=0.3) (Figure 3)

